Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) Operating Income: 2016-2024

Historic Operating Income for Denali Therapeutics (DNLI) over the last 9 years, with Dec 2024 value amounting to -$487.3 million.

  • Denali Therapeutics' Operating Income rose 2.06% to -$129.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$487.3 million, marking a year-over-year decrease of 147.76%. This contributed to the annual value of -$487.3 million for FY2024, which is 147.76% down from last year.
  • As of FY2024, Denali Therapeutics' Operating Income stood at -$487.3 million, which was down 147.76% from -$196.7 million recorded in FY2023.
  • In the past 5 years, Denali Therapeutics' Operating Income ranged from a high of $62.7 million in FY2020 and a low of -$487.3 million during FY2024.
  • Over the past 3 years, Denali Therapeutics' median Operating Income value was -$340.7 million (recorded in 2022), while the average stood at -$341.6 million.
  • Per our database at Business Quant, Denali Therapeutics' Operating Income skyrocketed by 129.42% in 2020 and then tumbled by 571.56% in 2021.
  • Denali Therapeutics' Operating Income (Yearly) stood at $62.7 million in 2020, then crashed by 571.56% to -$295.8 million in 2021, then declined by 15.21% to -$340.7 million in 2022, then soared by 42.27% to -$196.7 million in 2023, then tumbled by 147.76% to -$487.3 million in 2024.